Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR8 | P51685 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18739047 | 0.80 | KDM4E (0.39) | CCR1CCR8KDM4EPSMD14COPS5 | |
| SCHEMBL3558158 | 0.78 | BACE1 (0.41) | CCR1CCR8LMNAKDM4EPSMD14 | |
| SCHEMBL6422325 | 0.77 | PSMD14 (0.62) | NR4A2CCR1CCR8L3MBTL1KDM4E | |
| SCHEMBL27418389 | 0.77 | NR4A2 (0.38) | NR4A2CCR1CCR8L3MBTL1LMNA | |
| SCHEMBL4698412 | 0.77 | PSMD14 (0.39) | NR4A2CCR1CCR8L3MBTL1LMNA | |
| SCHEMBL5558125 | 0.77 | NR4A2 (0.38) | NR4A2CCR1CCR8L3MBTL1LMNA | |
| SCHEMBL3064498 | 0.77 | NR4A2 (0.46) | NR4A2CCR1CCR8L3MBTL1LMNA | |
| SCHEMBL4698452 | 0.77 | PSMD14 (0.44) | NR4A2CCR1CCR8L3MBTL1LMNA | |
| SCHEMBL22326654 | 0.77 | CCR1 (0.36) | CCR1CCR8L3MBTL1LMNAPDE10A | |
| SCHEMBL1666214 | 0.77 | TET2 (0.44) | CCR1CCR8LMNAKDM4EPSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111072555-B | Method for preparing heterocyclic sulfone organic compound | 苏州大学 | 2021-08-27 | — | — | CN | disclosed |
| CN-111072555-A | Method for preparing heterocyclic sulfone organic compound | 苏州大学 | 2020-04-28 | — | — | CN | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| EP-1663981-B1 | PIPERAZINYL-QUINOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007039219-A1 | QUINOLINE COMPOUNDS CAPABLE OF BINDING THE CB2 AND/OR THE 5-HT6 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| EP-1756083-A1 | 3-ARYLSULFONYL-QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027139-A1 | Piperazinyl-quinoline derivatives useful for the treatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | US | disclosed |
| EP-1663981-A1 | PIPERAZINYL-QUINOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| EP-1660483-A1 | 8-(1-PIPERAZINYL)-QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005113539-A1 | 3-ARYLSULFONYL-QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005030724-A1 | PIPERAZINYL-QUINOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005021530-A1 | 8- (1-PIPERAZINYL)- QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027139-A1 | Piperazinyl-quinoline derivatives useful for the treatment of cns disorders | PMP22, AQP4, GRIN2A | NR4A2 1617/4885CCR1 3056/4885CCR8 3108/4885 |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | NR4A2 2543/4885CCR1 3580/4885CCR8 589/4885 |
| US-20070249603-A1 | 3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR3B, HTR1A | NR4A2 1354/4885CCR1 1626/4885CCR8 2896/4885 |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | NR4A2 2543/4885CCR1 3580/4885CCR8 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.